Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ENvue Medical's Enterprise Value is €3.60 Mil.
ENvue Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-10.03 Mil. Therefore, ENvue Medical's EV-to-OCF for today is -0.36.
The historical rank and industry rank for ENvue Medical's EV-to-OCF or its related term are showing as below:
FRA:56R'
s EV-to-OCF Range Over the Past 10 Years
Min: -15.6 Med: -0.48 Max: 0.61
Current: -0.36
During the past 13 years, the highest EV-to-OCF of ENvue Medical was 0.61. The lowest was -15.60. And the median was -0.48.
FRA:56R's EV-to-OCF is ranked better than 60.59% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 7.895
vs FRA:56R: -0.36
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ENvue Medical's PE Ratio (TTM) for today is calculated as:
ENvue Medical's share price for today is €74.40.
ENvue Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-228.211.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ENvue Medical EV-to-OCF Related Terms
ENvue Medical EV-to-OCF Historical Data
* Premium members only.
The historical data trend for ENvue Medical's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ENvue Medical's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENvue Medical EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ENvue Medical's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ENvue Medical's EV-to-OCF falls into.
ENvue Medical's current Enterprise Value is €3.60 Mil.
ENvue Medical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENvue Medical (FRA:56R) has a EV-to-OCF of -0.36 as of Sep. 09, 2026. According to the industry distribution chart, ENvue Medical ranks #335 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 39.4%.
Is ENvue Medical's EV-to-OCF too high?
ENvue Medical's current EV-to-OCF is -0.36. Based on the distribution chart, ENvue Medical ranks #335 out of 850 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ENvue Medical has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does ENvue Medical's EV-to-OCF compare to RMSL and GCTK?
According to the Medical Devices & Instruments industry distribution chart, ENvue Medical ranks #335 out of 850 companies for EV-to-OCF. This puts ENvue Medical in the upper half of its industry. The industry median EV-to-OCF is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.90, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENvue Medical's current EV-to-OCF is -0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENvue Medical stock overvalued right now?
ENvue Medical (FRA:56R) has a current EV-to-OCF of -0.36. The stock's GF Value™ is €99.08, compared to a current price of €74.40 — trading 24.9% below its estimated fair value. The current EV-to-OCF is -0.36. ENvue Medical's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ENvue Medical (FRA:56R), the current EV-to-OCF is -0.36 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ENvue Medical (FRA:56R) Overvalued in 2026?
Based on GuruFocus' analysis, ENvue Medical stock appears to be undervalued.
The current stock price of €74.40 is trading 24.9% below its estimated GF Value™ of €99.08.
Key valuation signals for FRA:56R:
EV-to-OCF: -0.36
GF Value™: €99.08 vs. price of €74.40 (24.9% below fair value)
No single metric tells the full story. See the FRA:56R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.
46GF Score
Get the complete analysis for FRA:56R
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:56R has been successfully added to your 
